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A B S T R A C T
The use of real-time quantitative polymerase chain reaction (qPCR) in cancer research has
become ubiquitous. The relative simplicity of qPCR experiments, which deliver fast and
cost-effective results, means that each year an increasing number of papers utilizing this
technique are being published. But how reliable are the published results? Since the validity
of gene expression data is greatly dependent on appropriate normalisation to compensate
for sample-to-sample and run-to-run variation, we have evaluated the adequacy of normal-
isation procedures in qPCR-based experiments. Consequently, we assessed all colorectal
cancer publications that made use of qPCR from 2006 until August 2013 for the number of
reference genes used and whether they had been validated. Using even these minimal eval-
uation criteria, the validity of only three percent (6/179) of the publications can be adequately
assessed. We describe common errors, and conclude that the current state of reporting on
qPCR in colorectal cancer research is disquieting. Extrapolated to the study of cancer in gen-
eral, it is clear that themajority of studies using qPCR cannot be reliably assessed and that at
best, the results of these studies may or may not be valid and at worst, pervasive incorrect
normalisation is resulting in thewholesale publication of incorrect conclusions. This survey
demonstrates that theexistenceof guidelines, suchasMIQE, is necessary butnot sufficient to
address this problemand suggests that the scientific community should examine its respon-
sibility and be aware of the implications of these findings for current and future research.
ª 2014 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
1. Introduction
Since its introduction in 1992 (Higuchi et al., 1992), the real-time
quantitative polymerase chain reaction (qPCR) has become a
commonly used technique for detecting and measuring RNA
expression in cancer research. Despite the introduction of
next-generation sequencing (NGS), qPCR remains an essential
technique for confirmation of NGS findings. The perceived
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simplicity of qPCR experiments, which can deliver fast and cost-
effective results, has resulted in an increasing number of publi-
cations that utilize this technique. But how reliable are the pub-
lished results? PCR is comprised of several critical parameters
thatmust be evaluated carefully and optimized to obtainmean-
ingful and reproducible results (Derveaux et al., 2010; Tichopad
et al., 2009). In 2009 the Minimum Information for Publication
of Quantitative Real-Time PCR Experiments (MIQE) guidelines
were introduced to facilitate critical assessment of those param-
eters (Bustinet al., 2009). Theneed for theseguidelines is empha-
sized by a recently described example of conflicting results in
publications reporting inadequately transparent experimental
detail (Bustin et al., 2013). Endogenous control genes (or refer-
ence genes) are one of the crucial parameters incorporated in
theMIQE guidelines and their use is currently themost accurate
method for correcting variability associatedwith template input
and RT efficiency (Bustin et al., 2009). An important prerequisite
fora referencegene is that its expressionshould remainasstable
as possible. Furthermore, gene expression is not only highly tis-
sue specific but also dependent on the experimental setting
(Caradec et al., 2010; Radonic et al., 2004), which suggests that
it is highly unlikely that universal reference genes exist
(Vandesompele et al., 2002). Indeed, most well known reference
genes suchasGAPDHor b-actinarenot stably expressed (Bustin,
2000; Caradec et al., 2010; Greer et al., 2010; Suzuki et al., 2000;
Thellin et al., 1999; Warrington et al., 2000). Nevertheless, there
are numerous studies that continue to use these, and other
genes, without proper validation. Another consideration when
choosing a reference gene is dependent on the method of anal-
ysis. The DDCq method is currently the most commonly used
method for studies that report changes in the expression of
genes of interest relative to a reference gene (Dijkstra et al.,
2012; Schmittgen and Livak, 2008). In common with all other
relative quantification methods, this approach assumes two
basic conditions: (i) the efficiency of individual assays must be
consistent from one run to another and (ii) the effect of any var-
iations on Cq value must be equivalent for reference genes and
genes of interest (Schmittgen and Livak, 2008). It is therefore
essential that the efficiencies of the assays for all targets are
known and comparable and, should this not be the case that a
correction factor is applied. These assumptions do not apply to
the reporting of quantitative relative to target-specific standard
curves; nevertheless an inefficient assay is likely to be non-
robust, perform poorly and hence will result in increased vari-
ability of the results (Tichopad et al., 2004, 2003).
In the current paper we provide an assessment of the reli-
ability of published qPCR studies in all colorectal cancer-
associated publications that used qPCR between 2006 and
August 2013. The evaluation is based on an analysis of refer-
ence genes, since their rigorous selection and validation im-
plies both an understanding of the technique and a
willingness of the researcher to perform a well-designed
experiment.
2. Method
A PubMed search was performed to retrieve all English-
language publications using the keywords “colorectal cancer”
and “real-time PCR”/”qPCR” in the period between 01/01/2006
and 01/08/2013. Only full text publications, in which qPCRwas
used to assess the diagnostic, prognostic or predictive value of
mRNA or miRNA expression, were considered for this survey.
All publications were screened for: 1. Journal name, 2. Year of
publication, 3. Impact Factor (obtained from Web of Science:
http://isiknowledge.com/wos), 4. Type of original sample
(e.g. FFPE, frozen, blood), 5. qPCR starting material (RNA/
miRNA), 6. Name and accession number of reference gene(s),
7. Citation of PCR efficiencies (claimed comparable efficiency
and performed standard curves were accepted), 8. Use of
efficiency-dependent method of analysis (e.g. DDCq, DCq, Ra-
tio), 9. Total number of reference genes, 10. Validity testing of
reference gene(s), 11. Citation of MIQE, 12. Availability of on-
line supplemental qPCR related data. Screening was per-
formed by the four authors and to assure concordance in
screening each author screened ten publications initially
screened by another author.
Results were classified as follows:
 If they abided by the individual MIQE criteria being assessed
they were scored as a “1”’ if they did not as a “0”.
 The number of reference genes used to normalize the data
were recorded and scored "000 if no or only a single reference
gene was used. If multiple reference genes were used they
were scored as "100.
 A lack of clarity or complete absence of information in some
publicationsmade it impossible to score individual parame-
ters. Hence a third category, "other", was included which
comprises results that could not be scored in category "000
or "100.
Comparisons of the overall results in relation to the year of
publication or impact factor are depicted by changes in
compliance to the MIQE criteria.
3. Results
The initial PubMed based search to retrieve all publications on
“colorectal cancer” using “real-time PCR”/”qPCR” in the period
between 01/01/2006 and 01/08/2013 identified 378 publica-
tions. In total, 199 publications were excluded from the anal-
ysis because qPCR was not used to assess the diagnostic,
prognostic or predictive value of the expression (n ¼ 87), or
the methods were DNA based (n ¼ 87). Eighteen papers were
excluded because they did not fulfill the eligibility criteria
(i.e., cell line experiments, the aim of the publication being
finding general reference genes, knock-down checks, etc)
and we were unable to obtain the full text from seven papers,
even after contacting the corresponding author. This resulted
in 179 publications meeting our criteria and therefore being
suitable for reviewing (Figure 1).
The individual results for every publication are provided in
Supplemental data 1. There were fewer miRNA-based qPCR
experiments than those targeting mRNA based (resp. 28 and
151, Figure 1). Since all data on both miRNA and RNA were
comparable (data not shown), except for the used reference
genes (Table 1), the groups were analysed together. In general
(Figure 2), almost all studies used a similar strategy in per-
forming the experiment and reporting the experimental
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setting. Commercial assays were used in 32% of the published
experiments. In 92% of the publications, only a single refer-
ence gene was used. Validation of the reference genes and on-
line supplemental data were not reported in 87%e92% of the
publications. Crucially, 91% used an efficiency-dependent
method of analysis despite the fact that only 18% reported
the PCR efficiencies. Finally, the MIQE guidelines were cited
in only 1% of publications.
Figure 3 displays the results in relation to the year of pub-
lication. Besides a normal fluctuation over the years there is
no clear trend visible for any parameter, except possibly for
the use of the efficiency-dependent method of analysis.
When the data are stratified into two groups using either
2009 (the implementation of MIQE) or 2012 (when MIQE might
be expected to have started to have an impact) as a threshold
value it becomes clearer that none of the critical parameters
show any improvement.
The results in relation to the impact factor of the journal
are depicted in Figure 4, separated into two categories, those
with impact factors of <5 and 5. There were no differences
in any of the reported parameters, except for the more exten-
sive deposition of supplemental data in higher impact factor
journals.
Based on the assumption that users are expecting the effi-
ciencies of commercial assays to be tested by the producing
company, it might be expected that researchers would be
more inclined to assess the efficiency of the PCR for non-
commercial primers. However, the PCR efficiency is only
tested for 21% of the non-commercial assays, which is just
5% higher than for the commercial assays.
4. Discussion
Although qPCR is often described as a “gold standard” for gene
expression studies and has been used in thousands of pub-
lished papers, there are serious questions over its reliability,
reproducibility and the validity of conclusions based on this
technique (Bustin, 2010). The increasing focus on molecular
biomarkers has led to the publication of numerous papers us-
ing qPCR to identify and attempt to validate a wide range of
mRNA and miRNA markers for diagnostic, prognostic or pre-
dictive purposes in human cancers. But how sound are these
studies? Here we provide an assessment of the reliability of
published qPCR studies in relevant colorectal cancer-
associated publications that used qPCR between 2006 and
August 2013. The disturbing finding of this survey is that the
vast majority of publications provide insufficient information
to allow an assessment of the reliability of these qPCR exper-
iments. Considering that the survey is limited to reference
genes, the results are likely to be an underestimation of the
reporting quality of qPCR experiments.
A striking and commonly found limitation of qPCR experi-
ments is the number of reference genes that are used to
normalize qPCR data. It has become well-established that
the use of more than one reference gene increases the accu-
racy of the measurement compared to the use of a single
reference gene, especially when the aim is to show relatively
small fold-changes in RNA levels (Meyer et al., 2010;
Vandesompele et al., 2002). Furthermore, for large-scale
studies it has been established that the use of the mean
expression value is the best normalization strategy
(Mestdagh et al., 2009). However, 92% of the assessed publica-
tions use only a single reference gene, and only 6% use more
than two. Furthermore, only 23 (13%) out of the 179 publica-
tions report whether the chosen reference genewas validated.
Based on our finding that 70% of the publications on RNA
based qPCR use just one of three reference genes (ACTB/
GAPDH/18S, Table 1), it appears to be highly unlikely that
these have been validated. Several publications base the
choice of the reference gene either on other (non-comparable)
studies (Mazzoccoli et al., 2011) or on results frompublications
Figure 1 e A flow chart showing the selection of publications for this
study. More details can be found in the methods section.
Table 1 e Representation of the most commonly used reference
genes for qPCR experiments using RNA (A) and miRNA (B) as
starting material.
A
RNA
Total %
ACTB 53/165 32
GADPH 48/165 29
18S RNA 15/165 9
B2M 7/165 4
HPRT 6/165 4
Other 22/165 22
B
miRNA
Total %
RNU6B 16/36 44
GADPH 3/36 8
ACTB 3/36 8
RNU48 3/36 8
5S RNA 2/36 6
miR-16 2/36 6
Other 7/36 19
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identifying general reference genes (Andersen et al., 2011;
Herath et al., 2009; Mazzoccoli et al., 2011; Rubie et al., 2011,
2008). The use of either approach is ill-advised for several rea-
sons, a. the valid use of a reference gene is shown to be tissue-
and even experiment-specific, b. the efficiencies/validations
reported may not be repeated in a second study, c. the use
of the exact same reagents, instruments and protocols is not
always achievable, and d. if the referenced publication is not
published in an open access journal, claims may not be easily
corroborated (Caradec et al., 2010; Radonic et al., 2004). A
comprehensive disclosure of the method used does not guar-
antee a high quality experiment. One of the studies did
describe the validation of a reference gene (Koga et al., 2008)
and even though it was unstably expressed and therefore un-
suitable as a reference gene, it was still used for this purpose.
Furthermore, even though it has been established that the
best way to normalize miRNA expression is to use other miR-
NAs (Vandesompele et al., 2002), 52% and 16% of all
publications on miRNA expression use a small nuclear RNA
or an mRNA, respectively, as a (single) reference gene.
This study also reveals that 146/179 publications (82%) do
not mention PCR efficiencies of either target or the reference
genes, yet an extraordinary 135 of these 146 publications
(92%) use a method of analysis that is meaningless unless
PCR efficiencies are known. An example of such a method is
the DDCq-method, and one of the prerequisites for using
this method is comparable assay efficiencies for the reference
gene and gene of interest, all other instances require the appli-
cation of a correction factor (Schmittgen and Livak, 2008). It is
therefore essential to provide details of PCR efficiencies when
this approach is used. Failure to report PCR efficiencies does
not automatically mean these experiments are unreliable,
but is does make it impossible to assess the validity of the
data.
Consequently, the absence of information on assay effi-
ciencies alone renders 75% (135/179) of publications
Figure 2 e This stacked bar chart shows the distribution of the results per evaluation criteria. Each bar represents the accordance (1) or non-
compliance (0) with the specific criterion. All deviant cases (i.e. not specified, unclear) are represented in the category "other".
Figure 3 e Overall results in relation to the year of publication. The depicted line represents the percentage of publications that meet or report
information on the specific criterion.
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questionable. If the other assessed parameters are included,
173/179 (97%) provide inadequate information. This leaves a
mere six (3%) publications reporting sufficient experimental
detail to allow a reliable assessment of the qPCR data. Of
course, the fact that these six can be assessed for the validity
of the reference genes used does not automatically mean they
contain reliable results. The results of our analyses are similar
to those of a recent study looking at normalisation in the
context of the HepaRG cell line, which is widely used as an
alternative for primary human hepatocytes (Ceelen et al.,
2013). The authors of this study concluded that not one of
the 24 reviewed studies used a proper normalization method.
They also agree with another more general recent survey of
qPCR-based publications that comes to the same conclusion
(Bustin et al., 2013). Therefore, proper validation of reference
genesmight be lacking in themajority of all qPCR experiments
in any given setting.
An example of conclusions based on inadequate reporting
and possibly inappropriate experimental detail is the report
on the expression of CD133 in colorectal cancer patients
(Artells et al., 2010). It compares CD133mRNA levels of normal
and cancer samples using 18S rRNA as the single reference
gene using a commercial assay, concluding that CD133
mRNA expression is significantly higher in tumour compared
with normal tissue. There are a number of issues with these
data: first, despite using the DDCq normalization method,
there is no mention of PCR efficiency of either the gene of in-
terest or reference gene. Second, an analysis of the data shows
that the maximum relative expression difference between
paired tumour and normal tissue is only 2.5-fold, with 16/53
tissue pairs analysed having lower CD133 mRNA levels. This
kind of marginal fold-change requires careful application of
multiple validated reference genes and the use of a single,
unvalidated one is, at the very least, inadvisable. Third, 18S
rRNA genes have been described as a poor choice for use as
a reference gene for colorectal cancer, since not only do colo-
rectal cancers containmore ribosomes and rRNA than normal
tissue (Tsuji et al., 2002), but the regulation of rRNA synthesis
is independent from synthesis of mRNA (Radonic et al., 2004),
resulting in an expression pattern that differs from that of
mRNA (de Kok et al., 2005). Fourth, it has also been shown to
be one of the most variable reference genes in colorectal can-
cer (Sorby et al., 2010), although ironically an earlier report
contradicts this (Tsuji et al., 2002).
Strikingly, there was no correlation between the source of
an assay and the reporting of assay efficiencies. One might
have assumed that the supplier has already tested the effi-
ciencies of commercial assays; hence there would be less of
a need to test their efficiencies compared with non-
commercial self-designed assays, which obviously need to
be tested. Our results show that this is not so and again poses
the question whether researchers are failing to carry out basic
quality control analyses because they do not understand the
need to do so or because they just cannot be bothered.
The results of the current survey areworrying. If these data
are extrapolated to the study of cancer in general, one is
forced to conclude that almost all studies that use qPCR
cannot be reliably assessed and the results of these studies
might or might not be valid. Enormous amounts of money
and effort have been put into this kind of research over the
years while the practical implications are that new research
studies but also extensive research and development efforts
by pharmaceutical and/or biotechnology companies are
potentially based on inaccurate data. This conclusion agrees
with a recent observation that literature data on potential
drug targets should be viewed with caution, sincemost exper-
iments published in the peer-reviewed literature are not
reproducible (Prinz et al., 2011). In an area as important as can-
cer diagnostics there is a necessity to improve and the scien-
tific community should take its responsibility more
seriously. The existence of guidelines, such as MIQE, is not
sufficient; editors and reviewers should realize its importance
for current and future research. Methodological screening of
papers should be standard, especially in the current era of
seemingly limitless technical possibilities.
Appendix A.
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.molonc.2013.12.016.
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